Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Dimopoulos MA, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott FL, Pore N, Brown M, Wang F, Cheng LI, Kagiampakis I, Williams M, Kinneer K, Wu Y, Jiang Y, Kubiak RJ, Zonder JA, Larsen J, Sirdesai S, Yee AJ, Kumar S.
Dimopoulos MA, et al. Among authors: larsen j.
Leuk Lymphoma. 2024 Oct 15:1-12. doi: 10.1080/10428194.2024.2373331. Online ahead of print.
Leuk Lymphoma. 2024.
PMID: 39404476